Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 — — — — —
P/S ratio
— — 3,065.12 — — — — —
Altman Z″-Score (non-manufacturers)
— — 3.50 — — — — —
P/FCF ratio
— — 0.00 — — — — —
P/Operating CF
— — (25.14) — — — — —
P/B ratio
— — 0.00 — — — — —
EV/Sales
— — 1,313.57 — — — — —
EV/EBITDA
— — 0.00 — — — — —
EV/FCF
— — (2.25) — — — — —
Current Ratio
— 6.54 18.53 11.22 8.22 15.22 15.76 39.53
Net Debt/EBITDA
— 1.35 7.24 2.97 0.92 0.46 0.44 (0.11)
Debt/Equity
— 0.00 0.00 0.00 0.20 0.36 0.50 0.74
ROE
— 28.06% 162.35% (60.82%) (48.58%) (52.96%) (37.51%) (50.39%)
ROA
— (137.65%) (22.98%) (33.76%) (40.87%) (38.65%) (25.16%) (30.56%)
ROIC
— 0.00% 0.00% (96.17%) (80.86%) (64.02%) (33.19%) (40.13%)
Return on Tangible Assets
— (80.96%) (13.09%) (28.79%) (51.49%) (54.03%) (30.14%) (38.23%)
Average Days of Receivables
— — 0.00 — — — — —
Earnings Yield
— — (8.92%) — — — — —
Free Cash Flow Yield
— — (19.02%) — — — — —
Free Cash Flow per Share
— (9.29) (100.55) (33.96) (40.88) (15.79) (8.56) (5.49)
Book value per Share
— (11.63) (49.50) 104.76 56.15 34.72 26.03 17.08
Free Cash Flow
— (5.50) (80.43) (179.97) (264.75) (102.69) (55.70) (36.62)
EV/EBIT
— — 0.00 — — — — —
Other line items

Show all line items

Columns are period end dates